HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

J. Biol. Chem., Vol. 277, Issue 12, 9713-9721, March 22, 2002

This Article Abstract Full Text (PDF) All Versions of this Article: 277/12/9713    most recent M111161200v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Nguyen, V.-P. Articles by Krolewski, J. J. Search for Related Content PubMed PubMed Citation Articles by Nguyen, V.-P. Articles by Krolewski, J. J. Social Bookmarking                      What's this?

Stat2 Binding to the Interferon- Receptor 2 Subunit Is Not Required for Interferon- Signaling^*

Vinh-Phúc Nguyen^§, Abu Z. M. Saleh, Allison E. Arch, Hai Yan^¶, Flavia Piazza, John Kim, and John J. Krolewski^**

From the  Department of Pathology and the ^** Chao Family Comprehensive Cancer Center, University of California, Irvine, Irvine, California 92697, the ^¶ Johns Hopkins Oncology Center, Johns Hopkins University, Baltimore, Maryland 21231, and the  Department of Pathology, Columbia University, College of Physicians and Surgeons, New York, New York 10032

Received for publication, November 21, 2001, and in revised form, January 8, 2002

	ABSTRACT

TOP ABSTRACT INTRODUCTION MATERIALS AND METHODS RESULTS DISCUSSION REFERENCES

The interferon- (IFN) receptor consists of two subunits, the IFN receptor 1 (IFNaR1) and 2 (IFNaR2) chains. Following ligand binding, IFNaR1 is phosphorylated on tyrosine 466, and this site recruits Stat2 via its SH2 domain. In contrast, IFNaR2 binds Stat2 constitutively. In this study we have characterized the Stat2-IFNaR2 interaction and examined its role in IFN signaling. Stat2 binds the major IFNaR2 protein but not a variant containing a shorter cytoplasmic domain. The interaction does not require a STAT SH2 domain. Both tyrosine-phosphorylated and non-phosphorylated Stat2 bind IFNaR2 in vitro; however, relatively little phosphorylated Stat2 associates with IFNaR2 in vivo. In vitro binding assays defined IFNaR2 residues 418-444 as the minimal interaction domain and site-specific mutation of conserved acidic residues within this domain disrupted in vitro and in vivo binding. An IFNaR2 construct carrying these mutations was either (i) overexpressed in 293T cells or (ii) used to complement IFNaR2-deficient U5A cells. Unexpectedly, the activity of an IFN-dependent reporter gene was not reduced but, instead, was enhanced up to 2-fold. This suggests that this particular IFNaR2-Stat2 interaction is not required for IFN signaling, but might act to negatively inhibit signaling. Finally, a doubly truncated recombinant fragment of Stat2, spanning residues 136-702, associated with IFNaR2 in vitro, indicating that the interaction with IFNaR2 is direct and occurs in a central region of Stat2 marked by a hydrophobic core.

	INTRODUCTION

TOP ABSTRACT INTRODUCTION MATERIALS AND METHODS RESULTS DISCUSSION REFERENCES

Type I interferons (IFNs),¹ including multiple interferon- (IFN) isoforms and interferon- (IFN), bind a common receptor complex consisting of two subunits, interferon- receptor 1 (IFNaR1) and interferon- receptor 2 (IFNaR2). IFNaR1 displays low affinity for most human IFN isoforms and appears to be primarily a signal transducing subunit (1, 2). The other subunit, IFNaR2, mediates both ligand binding and signaling (3-5). It is expressed as three variants: a soluble receptor (5), a short transmembrane form (5), and a long transmembrane form believed to be the physiologically relevant receptor (3, 4). The short and long transmembrane forms are referred to as IFNaR2-1 and IFNaR2-2, respectively. IFNaR2-1 is usually expressed at lower levels than IFNaR2-2 and may exert a dominant negative effect on IFN signaling, although its precise role is unclear (6).

IFN receptor subunits lack intrinsic enzymatic activity, instead relying on members of the Janus tyrosine kinase (JAK) family to transduce signals. Genetic complementation experiments have linked two JAKs, Tyk2 and Jak1, to IFN signaling (7, 8), and biochemical studies subsequently demonstrated constitutive and direct association of these JAKs with the IFNaR1 and IFNaR2 subunits, respectively (9-12). Two members of the signal transducer and activator of transcription (STAT) family, Stat1 and Stat2, have also been implicated (13, 14). Signaling begins with IFN binding, triggering receptor oligomerization and juxtaposing associated JAKs. A series of auto- and/or transphosphorylations result in Jak1 and Tyk2 activation (8, 11, 15) and phosphorylation of tyrosine residue 466 on IFNaR1 (10, 12, 16). Once phosphorylated, this tyrosine recruits Stat2 in an SH2-dependent manner (10, 17). Activated Tyk2 or Jak1 phosphorylate Stat2 on tyrosine that, in turn, recruits Stat1 to the receptor (10, 18). Following Stat1 phosphorylation, the two STATs subsequently heterodimerize via SH2-phosphotyrosine interactions (19, 20). With the p48/IRF9 protein, Stat1-Stat2 heterodimers form the interferon-stimulated gene factor 3 complex (14, 21, 22), which binds to the interferon-stimulated responsive element (ISRE) to direct transcription.

Latent STATs were initially believed to exist as monomers in the cytoplasm, but recent studies indicate that they exist primarily in high molecular weight complexes (23, 24). In this regard, constitutive association of Stat2 with IFNaR2 has been reported, and termed "pre-docking" (25). Although it has been suggested that this interaction facilitates the subsequent SH2 domain-dependent Stat2 recruitment, the biological significance of this association remains unclear. Therefore, we sought to delineate the Stat2 interaction domain on IFNaR2 and investigate its role in IFN signaling. We have found that the minimal Stat2 binding region is between residues 418 and 444 of IFNaR2, although a larger domain (residues 340-462) is required for maximal binding. Mutation of conserved acidic amino acids corresponding to residues 435-438 disrupts IFNaR2 binding to Stat2. Importantly, expression of these mutated IFNaR2 constructs in two separate cell systems demonstrates that ISRE-driven reporter gene activity is increased relative to cells expressing the wild-type receptor. Thus, this interaction is dispensable for effective IFN signaling and instead might function in the negative regulation of such signaling.

	MATERIALS AND METHODS

TOP ABSTRACT INTRODUCTION MATERIALS AND METHODS RESULTS DISCUSSION REFERENCES

Reagents, Viruses, and Cells-- The following antibodies were used: 4G10, against phosphotyrosine (Upstate Biotechnology); SC-138, against glutathione S-transferase (GST) (Santa Cruz Biotechnology); SC-805, against the influenza virus hemagglutinin (HA) epitope (Santa Cruz Biotechnology) (26); H15, against the polyhistidine tag epitope (Santa Cruz Biotechnology); T20220, against Tyk2 (BD Transduction Laboratories); J24320, against Jak1 (BD Transduction Laboratories); polyclonal rabbit antisera against the carboxyl terminus of Tyk2 (11); polyclonal rabbit antiserum against Stat2 (C. Schindler, Columbia University, College of Physicians and Surgeons, New York, NY) (14); and AC-15 against -actin (Sigma). Recombinant IFN2 was from M. Brunda (Hoffmann-La Roche, Nutley, NJ). Baculoviruses encoding Stat1, Stat2, and Jak2 (12) were used to infect Sf9 cells (Invitrogen) (27). Four human cell lines, embryonic kidney 293T cells (H. Young, Columbia University, College of Physicians and Surgeons, New York, NY), osteogenic sarcoma U20S cells (ATCC, Manassas, VA), IFNaR2-deficient U5A cells (4), and 2fTGH cells, the parental line for U5A cells, containing wild-type IFNaR2 (the latter two lines are from G. Stark, Lerner Research Institute, Cleveland Clinic Foundation), were all maintained as adherent cultures in Dulbecco's modified Eagle's medium plus 10% heat-inactivated fetal calf serum.

Expression Constructs-- Fragments of the IFNaR2 cytoplasmic domain were generated by PCR and were cloned, sequenced, and transferred into an appropriate pGEX vector (Amersham Biosciences) to encode GST-IFNaR2 fusion proteins. To create site-specific mutants the overlapping PCR technique (28) was used to generate DNA fragments (spanning residues 376-462) with alanine substitutions at positions 435-438 (mutant 1, DDED to AAAA), and 440-443 (mutant 2, DDLE to AAAA) of IFNaR2, respectively. The full-length IFNaR2 cDNA and the corresponding 435-438 mutant were cloned into pMT2T for expression in human cells (29). A DNA fragment flanked by XhoI sites, encoding amino acids 136-702 of Stat2, was PCR-amplified using Pfu polymerase (Stratagene), cloned, sequenced, and then transferred into pET15b (Novagen) for expression in bacteria. Truncated Stat2 constructs (corresponding to residues 1-293, 1-323, and 123-517, respectively) were generated using convenient restriction sites and cloned into pMT2T. The eukaryotic expression construct encoding a constitutively expressed -galactosidase gene has been previously described (30). The luciferase gene construct is under the control of an ISRE from the ISG-15 gene (31).

Recombinant Proteins-- Escherichia coli DH5, containing the appropriate pGEX-IFNaR2 construct, was grown at 37 °C to log phase and induced at 30 °C with 0.1 mM isothiogalactopyranoside (IPTG) for 3-4 h. Pelleted bacteria, resuspended in STE (10 mM Tris-HCl, pH 8.0, 150 mM NaCl, and 1 mM EDTA) containing 150 µg/ml of lysozyme and 1 mM phenylmethylsulfonyl fluoride, were sonicated. Inclusion bodies were pelleted and solubilized in Sarkosyl (32) and stored at 80 °C in STE containing 1% Triton X-100, 0.1% sarcosyl, 10% glycerol. Purification of His-tagged Stat2-(136-702) will be described in detail.² Briefly, E. coli BL21 (DE3) expressing His-tagged Stat2 protein were grown at 37 °C and induced at 30 °C with IPTG. Following cell lysis and centrifugation, the protein was purified by chromatography on hydroxylapatite (Bio-Rad) and nickel resin (Invitrogen). Stat2 was prepared from baculovirus-infected Sf9 cells 48 h post-infection or from calcium phosphate transfected 293T cells 48 h post-transfection, by lysing cells in TBES/1% Nonidet P-40 buffer (20 mM Tris-HCl, pH 7.5, 137 mM NaCl, 5 mM EDTA, 1% Nonidet P-40) followed by centrifugation to remove nuclei and debris.

In Vitro Binding Assay-- GST-IFNaR2 fusions, immobilized on glutathione-agarose beads (Sigma), were washed with STE, 1% Triton X-100, 0.1% Sarkosyl, and incubated with recombinant Stat2. Following washes in TBES/1% Nonidet P-40 buffer, complexes were eluted in sample buffer and immunoblotted as described below.

Eukaryotic Cell Transfection-- Transient transfection of subconfluent 293T cells (~8 × 10⁶ cells on 15-cm dishes), U2OS cells (~1 × 10⁶ cells on 10-cm dishes), stable U5A derivatives created as described below (~8 × 10⁵ cells on 10-cm dishes), or 2fTGH cells (~8 × 10⁵ cells on 10-cm dishes) was performed using calcium-phosphate precipitates and the indicated amount(s) of plasmid DNA. In some experiments, 10-cm dishes of 293T cells (~3 × 10⁶ cells) were transiently transfected with 20 µg of the appropriate plasmid DNA employing LipofectAMINE Plus (Invitrogen), according to the manufacturer's instructions. Forty-eight hours post-transfection, transiently transfected cultures were subjected to immunoprecipitation and/or immunoblotting or reporter gene analysis, as described below. Stable transfectants of U5A cells were created by co-transfecting 10-cm dishes (~8 × 10⁵ cells) with 10 µg of HA-tagged pMT2T-IFNaR2 expression constructs and 1 µg of pcDNA3.1(+), which carries a neomycin resistance gene. Forty-eight hours post-transfection cells were diluted into medium containing 400 µg/ml G418 (Invitrogen). Individual clones were propagated and screened by immunoblotting cytoplasmic lysates with an anti-HA antibody to identify lines expressing IFNaR2 proteins. Stable derivative cell lines were periodically cultured in the presence of G418 and monitored by immunoblotting with anti-HA antibodies to ensure the continued expression of the exogenous IFNaR2 constructs.

Immunoprecipitation and Immunoblotting-- Nearly confluent cultures were lysed in TBES/1% Nonidet P-40 plus 0.2 mM phenylmethylsulfonyl fluoride. Nuclei, debris, and cell membranes were removed by centrifugation to yield a mainly cytoplasmic protein extract. In some cases portions of these crude extracts were mixed with sample buffer, resolved by SDS-PAGE, transferred to nitrocellulose (Osmonics), blocked in either 5% nonfat dry milk or 3% bovine serum albumin, and sequentially probed with an appropriate primary antibody, followed by a secondary antibody linked to horseradish peroxidase. Bands were visualized by chemiluminescence (Pierce Super Signal Substrate). In other cases proteins were first immunoprecipitated by incubating the cytoplasmic lysates with appropriate antibodies and protein A-Sepharose beads (Sigma). The antibody-protein complexes were collected by centrifugation, washed, eluted by boiling in sample buffer, and immunoblotted as described above. The primary antibody dilutions used for immunoblotting were: 1:3000 for 4G10, 1:10,000 for SC805, H15, SC-138, and AC-15, and 1:20,000 for the anti-Stat2 polyclonal antibody. To monitor protein loading on some immunoblots, membranes were stripped, washed, and reprobed with appropriate antibodies.

Reporter Gene Assays-- In the case of U2OS cells, duplicate 10-cm dishes were transfected with 10 µg of a -galactosidase construct, 10 µg of an ISRE-luciferase construct, and 30 µg of the appropriate expression construct. Three to four sets of duplicate dishes were used for each expression construct in a single experiment, which were performed on four separate occasions (n = 13). Thirty-four hours post-transfection, one dish was treated with 300 units of IFNa2/ml for 14 h, whereas the other dish was left untreated. Cells were washed, lysed in Reporter Lysis Buffer (Promega), and frozen on dry ice. After thawing, debris were removed by centrifugation, and a portion of each lysate was assayed for luciferase activity using firefly luciferase assay substrate (Promega) in an auto-injecting luminometer (Turner Design). The remainder of each lysate was assayed for -galactosidase activity using a previously described protocol (17) adapted for microtiter plates. Fold-induction is calculated by dividing luciferase activity in IFN-treated cultures by the activity in companion untreated cultures after normalizing each luciferase value with the appropriate -galactosidase value. Reporter gene assays on stable transfectants of U5A cells or on 2fTGH cells were performed similarly on 10-cm dishes using 5 µg of the -galactosidase construct and 10 µg of the ISRE-luciferase construct. IFN treatment (1000 units/ml) was for 6 h.

Statistical Analysis-- Data from the luciferase reporter gene assays were analyzed by an unpaired Student's t test employing Statview software (Abacus Concepts).

Densitometry-- Non-saturating exposures of immunoblot autoradiograms were scanned in Photoshop version 6.0 (Adobe Systems) and pixel density quantitated using NIH Image version 1.62 software. Background pixel density was sampled in multiple spots, and the average background density was subtracted to obtain a corrected pixel density for each scanned band. Relative Stat2 protein levels were determined by dividing the corrected Stat2 pixel density by the corresponding corrected -actin pixel density.

	RESULTS

TOP ABSTRACT INTRODUCTION MATERIALS AND METHODS RESULTS DISCUSSION REFERENCES

Stat2 Specifically Interacts with IFNaR2-2 in Vitro-- IFNaR2-1 and IFNaR2-2 (3, 4) are identical across their extracellular and transmembrane domains, as well as within the first 15 amino acids of the cytoplasmic domain, but then they diverge. To determine whether Stat2 interacts specifically with IFNaR2-2, immobilized GST fusion proteins containing the cytoplasmic domain of IFNaR2-2, IFNaR2-1, or IFNaR1 were incubated with a human Stat2-containing Sf9 cell extract, and complexes were immunoblotted with anti-Stat2 antiserum. A strong interaction was detected with GST-IFNaR2-2 (Fig. 1A, lane 5), but not with GST, GST-IFNaR1, or GST-IFNaR2-1 (Fig. 1A, lanes 2-4), essentially as previously observed (25, 33). We did not observe consistent binding of baculovirus-produced Stat1 and GST-IFNaR2-2 (data not shown). Next, to investigate whether phosphorylated Stat2 can bind IFNaR2-2, we coinfected Sf9 cells with recombinant baculoviruses encoding Jak1 and Stat2. Under these conditions Stat2 is tyrosine-phosphorylated in a manner similar to that seen following IFN treatment (10, 34). Employing the same in vitro binding assay, we observed a strong association between phosphorylated Stat2 and IFNaR2-2 (Fig. 1B, lane 3).

View larger version (9K): [in this window] [in a new window]   Fig. 1.   In vitro binding of Stat2 to IFNaR2. A, GST or GST fusions containing the cytoplasmic domain of IFNaR1, IFNaR2-1, or IFNaR2-2 were bound to beads, incubated with Stat2-containing lysates, and immunoblotted with anti-Stat2 antiserum. Equal amounts of GST protein were present in each lane, as judged by staining of the blotting membrane (data not shown). An aliquot of the Stat2 lysate equivalent to 20% of that used in the binding assays was loaded in lane 1. B, tyrosine-phosphorylated Stat2 (Stat2-P), was used in binding assays as in A. C, same as B except Stat2 with a point mutation in the SH2 domain (Stat2-R601K) was used.

Docking of Stat2 to IFNaR1 requires phosphorylation of tyrosine residue 466 on IFNaR1 as well as an intact Stat2 SH2 domain (10). Because it is unlikely that the bacterially expressed GST fusions employed in Fig. 1 are tyrosine-phosphorylated, it is similarly unlikely that IFNaR2 phosphorylation is required for the interaction with Stat2. Thus, we anticipated that the Stat2 SH2 domain would also be superfluous for the Stat2-IFNaR2-2 interaction. As expected, a strong signal was observed (Fig. 1C, lane 3) when the in vitro binding assay was performed with lysate from cells infected with a Stat2 baculovirus bearing an inactivating SH2 domain mutation (R601K) (10).

Mapping the Minimal Stat2 Binding Domain on IFNaR2-- Fig. 1 indicates that Stat2 specifically interacts with IFNaR2-2. Therefore, we employed the IFNaR2-2 subunit, referred to hereafter as IFNaR2 for the remainder of our studies. To delineate the Stat2 binding domain on IFNaR2, a panel of GST fusion proteins encoding portions of the cytoplasmic domain was used in similar in vitro binding assays (Fig. 2A). Truncation of IFNaR2 from the carboxyl terminus to residue 444 (Fig. 2B, lane 4), or from the amino terminus to residue 340 (Fig. 2B, lane 7) did not affect binding. However, a doubly truncated construct (340-444) displayed some reduction in binding (Fig. 3, compare lanes 4 and 3). Further truncation from the amino terminus revealed that a 25-amino acid fragment (418-444) of IFNaR2 bound Stat2, albeit at reduced efficiency (Fig. 2B, lane 11). These data suggest that residues in this small region are critical for the interaction. Alignment of human and murine IFNaR2 revealed substantial homology, including a block (435-438; DDED) containing four acidic residues (Fig. 3A). To test the role of these acidic residues two mutants were created by substituting alanine for either these four amino acids (designated mutant 1), or for another, non-conserved block of mainly acidic amino acids (mutant 2). Stat2 binding to IFNaR2 was diminished when alanine substitution was made at positions 435-438 (Fig. 3B, compare lanes 7 and 6) but not when similar changes were made at the non-conserved residues (Fig. 3B, lane 8).

View larger version (30K): [in this window] [in a new window]   Fig. 2.   The minimal Stat2 interaction domain on IFNaR2 spans residues 418-444. A, summary of in vitro binding of Stat2 to GST-IFNaR2 fusions. The portion of the cytoplasmic domain in each construct is illustrated, with corresponding amino acids (left-hand column) and binding activity (right-hand column). The relative binding activity ( to +++) is based on visual assessment in multiple independent experiments (Figs. 2B and 3B are representative examples). For the two site-specific mutants the acidic residues converted to alanine are indicated below the construct. B, in vitro binding of IFNaR2 to Stat2. GST proteins spanning the indicated residues were used in binding assays as described in Fig. 1. The lower half of each immunoblot was probed with anti-GST antibody to verify that equal amounts of GST proteins were used (data not shown). Lanes 1-7, 8-12, and 13-17 represent separate experiments. For each, 20% of the amount of Stat2 employed in the binding assays was loaded in lanes 1, 8, and 13, respectively. The molecular masses (in kDa) of co-migrated standards are indicated on the left.

View larger version (39K): [in this window] [in a new window]   Fig. 3.   Conserved acidic IFNaR2 residues are required for Stat2 binding. A, comparison of human and murine IFNaR2 between residues 417 and 449. Dashes represent gaps introduced to optimize alignment. Vertical bars indicate identical residues. Residues that were converted to alanine in mutants 1 and 2 are underlined. B, mutation of acidic IFNaR2 residues disrupt Stat2 binding in vitro. In vitro binding was performed as described in Figs. 1 and 2. The lower half of each immunoblot was probed with anti-GST antibody to verify equal loading (data not shown). The molecular masses (in kDa) of co-migrated standards are indicated on the left. The diffuse bands in lanes 5 and 6 are apparently artifacts, as they were not observed in replicate experiments (data not shown).

Mutation of Acidic Residues Disrupts Stat2 Binding to IFNaR2 in Vivo-- The in vitro binding data prompted us to examine if mutation of residues 435-438 also decreased binding in vivo. Constructs encoding Stat2 and HA-tagged wild-type (wt) or mutant 1 (m1) IFNaR2 proteins were transfected alone or in combination into 293T cells. Co-immunoprecipitation of Stat2 and IFNaR2 was significantly reduced in cells expressing m1 IFNaR2 (Fig. 4A, compare lanes 5 and 6), indicating that acidic residues at positions 435-438 of IFNaR2 are critical for association both in vitro and in vivo.

View larger version (15K): [in this window] [in a new window]   Fig. 4.   Stat2 associates with IFNR2 in vivo. Plasmid DNA (70 µg) constructs encoding Stat2, HA-tagged wild-type IFNaR2 (HA-wt IFNaR2), and HA-tagged mutant 1 IFNaR2 (HA-m1 IFNaR2) were transfected either alone or together into 293T cells on 15-cm dishes, as indicated. Empty expression vector was used to keep the total amount of transfected DNA constant. A, immunoprecipitation was carried out with an anti-HA antibody followed by immunoblotting with anti-Stat2 antiserum. Aliquots of transfected cell cytoplasmic extracts (Cyt. extracts) were directly analyzed by immunoblotting with an anti-HA antibody (B) or anti-Stat2 antiserum (C). The molecular masses (in kDa) of co-migrated standards are indicated on the left.

Effect of IFN Treatment on the Stat2-IFNaR2 Interaction-- As seen in Figs. 1-4, the Stat2-IFNaR2 association appears to be constitutive and therefore ligand-independent. However, to investigate the effect of IFN treatment on the interaction, transfected cells overexpressing Stat2 and HA-tagged wt or m1 IFNaR2 were treated with IFN. Co-immunoprecipitation analysis indicates that Stat2 association with wt IFNaR2 increases following ligand binding (Fig. 5A, compare lanes 4 and 3). However, in other experiments we observed little or no increase (Fig. 5E, compare lanes 3 and 4), suggesting that IFN treatment has a slight effect on the amount of Stat2 bound to IFNaR2. Stat2 binding to the m1 IFNaR2 construct was minimally detectable following IFN treatment (Fig. 5A, lane 6) but, as seen in Fig. 4, was greatly reduced compared with wt IFNaR2 (Fig. 5A, compare lanes 4 and 6).

View larger version (21K): [in this window] [in a new window]   Fig. 5.   Effect of IFN stimulation on the Stat2-IFNaR2 interaction. Transfection was carried out as in the legend to Fig. 4, except that duplicate dishes were prepared for each set of constructs. One dish was left untreated, and the other was stimulated with 1000 units of IFN2/ml for 20 min, as indicated. A, extracts were immunoprecipitated with anti-HA antibody, followed by immunoblotting with anti-Stat2 antiserum. In addition, aliquots of cytoplasmic extracts were analyzed by immunoblotting with anti-HA (B), or anti-Stat2 antibodies (C) to monitor protein levels. In panel B, the m1 IFNaR2 construct migrated slightly faster than the wt construct for unknown reasons. D, in a separate experiment, 293T cells were similarly transfected and treated with IFNa2, as indicated. In this case, lysates were divided in half and immunoprecipitated separately with anti-HA (lanes 1-4) or anti-Stat2 (lanes 5-8) antibodies, and immunoblotted with an anti-phosphotyrosine antibody. The faster migrating band in the anti-Stat2 lanes is tyrosine-phosphorylated Stat1, which co-immunoprecipitates with tyrosine-phosphorylated Stat2. The filters were reprobed with anti-Stat2 antiserum (E). In addition, for some samples, aliquots of cytoplasmic extracts were directly analyzed by immunoblotting with an anti-HA antibody (F). The molecular masses (in kDa) of co-migrated standards are indicated on the left.

Both phosphorylated and non-phosphorylated Stat2 bound GST-IFNaR2 in vitro (Fig. 1, A and B). To determine whether this occurs in vivo cells transiently co-expressing Stat2 and wt IFNaR2 were again treated with IFN. Part of each extract was immunoprecipitated with anti-HA antibody, and co-immunoprecipitating tyrosine-phosphorylated Stat2 was detected by immunoblotting with an anti-phosphotyrosine antibody (Fig. 5D, lanes 1-4). The remainder of each extract was immunoprecipitated with anti-Stat2 antiserum and immunoblotted with an anti-phosphotyrosine antibody (Fig. 5D, lanes 5-8). A small fraction of tyrosine-phosphorylated Stat2 associated with IFNaR2 (Fig. 5D, compare lanes 4 and 8). Reprobing the immunoblot in Fig. 5D with anti-Stat2 antiserum indicates that, as expected, only a portion of the Stat2 protein binds the receptor (Fig. 5E, compare lanes 3 and 4 with lanes 7 and 8). Factoring in the relative recovery of Stat2 revealed by comparing Fig. 5, D and E, it appears that phosphorylated Stat2 does not preferentially associate with IFNaR2.

Overexpression of Mutant 1 IFNaR2 Increases Stat2 Phosphorylation-- To determine whether expression of m1 IFNaR2 affects IFN signaling, we transiently expressed this mutant receptor in 293T cells and measured tyrosine phosphorylation of endogenous Stat2. We reasoned that expressing the mutant receptor at high levels would increase the likelihood that receptor complexes containing both m1 IFNaR2 and IFNaR1 will form, allowing us to determine the effect of this mutation on various aspects of JAK-STAT signaling. Endogenous Stat2 was phosphorylated after IFN stimulation (Fig. 6A, lanes 2, 4, and 6), as expected. Moreover, its phosphorylation increased in m1 IFNaR2-expressing cells relative to those expressing wt IFNaR2 or those transfected with empty vector (Fig. 6A, compare lane 6 to lanes 4 or 2, respectively). The reason for the increase in Stat2 tyrosine phosphorylation in cells transfected with the wt IFNaR2 construct, relative to vector-transfected cultures, is not known. It is possible that the level of IFNaR1 exceeds that of IFNaR2. Therefore, overexpression of IFNaR2 might increase the level of functional receptor heterodimer thereby increasing the responsiveness of the transfected cells. To gain further insight, kinetic experiments were carried out, extending IFN stimulation to 60 min. Stat2 phosphorylation appeared to rise to a higher level and sustain that level for a longer period of time in cells expressing m1 IFNaR2 compared with counterparts expressing wt IFNaR2 (Fig. 6C, compare lanes 2 and 3 with 5 and 6). Note that the effect of m1 IFNaR2 on Stat2 phosphorylation (panel C) may be underestimated in this experiment as these transfectants apparently expressed lower levels of m1 IFNaR2 relative to the wild type (Fig. 6E).

View larger version (25K): [in this window] [in a new window]   Fig. 6.   Overexpression of m1 IFNaR2 enhances IFN-induced Stat2 phosphorylation. A, LipofectAMINE Plus was used to transiently transfect 10-cm dishes of 293T cells with 20 µg of plasmid DNA encoding the indicated gene constructs. Forty-eight hours post-transfection, cells were either left untreated (lanes 1, 3, and 5) or treated with 1000 units of IFN2/ml for 20 min (lanes 2, 4, and 6). Extracts were immunoprecipitated with anti-Stat2 antiserum and immunoblotted with an anti-phosphotyrosine antibody. A short exposure, as well as a 6-fold longer exposure of the same blot is shown. B, the filter in A was stripped and reprobed with an anti-Stat2 antibody. C, cells were transfected, treated with IFN2, immunoprecipitated and immunoblotted, as in A, except that different time points were assayed, as indicated. D, the filter in C was stripped and reprobed with an anti-Stat2 antibody. E, aliquots of whole cell lysates were directly analyzed by immunoblotting with an anti-HA antibody.

We performed experiments similar to those shown in Fig. 6, A and B to examine the IFN-induced tyrosine phosphorylation of Jak1, the tyrosine kinase associated with the IFNaR2 subunit. There was no discernable difference in the level of induced Jak1 tyrosine phosphorylation in cells transfected with m1 IFNaR2 relative to those receiving wt IFNaR2 or vector (data not shown). Although IFNaR2 has been reported by others to be tyrosine-phosphorylated in response to IFN treatment (35-37), we did not detect tyrosine phosphorylation of transfected wt or m1 IFNaR2 (data not shown). In this regard it remains possible that our experiments may lack the sensitivity to detect IFNaR2 tyrosine phosphorylation, that the level of phosphorylation is low in this particular cell line, or that the signal from phosphorylated IFNaR2 is diluted by IFNaR2 molecules that are not part of the functional receptor complex. Finally, IFN-induced tyrosine phosphorylation of the Tyk2 tyrosine kinase, which associates with IFNaR1, was not different in cells transfected with wt or m1 IFNaR2 (data not shown).

Disruption of the Stat2-IFNaR2 Interaction Culminates in Increased IFN-dependent Transcription-- Next, we examined ISRE-dependent reporter gene activity (31, 38). Adenovirus-transformed 293T cells cannot be used in such assays because viral E1A binds p300/CBP, a Stat1- and Stat2-interacting transcriptional coactivator, blocking IFN-mediated transcription (39, 40). Therefore, U2OS cells were co-transfected with an ISRE-driven luciferase reporter, a constitutive -galactosidase plasmid, and constructs encoding wt or m1 IFNaR2. In cells transfected with empty vector, IFN increased luciferase activity 7-fold (Fig. 7, left column). Similar treatment resulted in a 12-fold induction in wt IFNaR2-expressing cells (Fig. 7, middle column). This increase, relative to vector-transfected cultures, is similar to the effect seen in Fig. 6, and again its cause is unknown. Transcriptional activity was enhanced 18-fold in the presence of the m1 IFNaR2 subunit (Fig. 7, right column), statistically higher than in cells expressing either the wild-type receptor or empty vector. These results demonstrate that signaling is enhanced when the Stat2 interaction with IFNaR2 is severely impaired.

View larger version (39K): [in this window] [in a new window]   Fig. 7.   Overexpression of m1 IFNaR2 enhances IFN-dependent reporter gene transcription. U2OS cells were co-transfected with empty expression vector or constructs encoding wt or m1 IFNaR2, an ISRE-containing reporter plasmid, and a vector constitutively expressing -galactosidase, treated with IFN, and assayed for luciferase and -galactosidase activities, as described under "Materials and Methods." Bars show the mean (n = 13) fold-increase in IFN-dependent luciferase activity relative to untreated cells, normalized for -galactosidase activity. Error bars represent the standard error of the mean. An asterisk indicates that the m1 IFNaR2-transfectants display a statistically significant increase in induced luciferase activity compared with both the wt IFNaR2-expressing cells, or cells transfected with empty vector (p < 0.05 or p < 0.0004, respectively).

Complementation of IFNaR2-deficient Cells with Mutant 1 IFNaR2 Also Enhances IFN-dependent Transcription-- One potential shortcoming of the data in Fig. 7 is the possibility that the endogenous, wild-type IFNaR2 receptor subunit is still playing a role in the signaling events occurring in those cells overexpressing m1 IFNaR2. To address this issue, and to provide independent confirmation of the physiologic function of the Stat2 binding site on IFNaR2, the wild-type and mutant forms of IFNaR2 were introduced into the U5A cell line, which does not express IFNaR2 (4). Stable transfectants were expanded and assayed for expression of IFNaR2, using an anti-HA antibody. Fig. 8A shows the characterization of a single clone expressing wild-type IFNaR2 and two independent clones expressing m1 IFNaR2. Because we were unable to identify wt and m1 clones expressing exactly the same amount of protein, we examined two separate clones, expressing higher and lower amounts, respectively, of m1 IFNaR2 (relative to a single wild-type-expressing clone), to evaluate potential dosage effects.

View larger version (14K): [in this window] [in a new window]   Fig. 8.   Complementation of U5A cells with m1 IFNaR2 enhances IFN-dependent transcription. A, stable IFNaR2 transfectants of U5A cells express similar levels of HA-tagged IFNaR2. Cells were collected, counted, lysed, and the lysates loaded directly onto a gel and immunoblotted with an anti-HA antibody. Lanes 1 and 2 contain lysate from 7.5 × 105 cells; lanes 3 and 4 contain lysate from 3.8 × 105 cells. The position of HA-tagged IFNaR2 is indicated. B, IFN-dependent reporter gene transcription is increased in U5A cell lines expressing m1 IFNaR2, relative to U5A cells complemented with wild-type IFNaR2. U5A derivatives expressing the indicated IFNaR2 constructs as well as the parental 2fTGH cells were transiently co-transfected with an ISRE-containing reporter plasmid and a vector constitutively expressing -galactosidase, treated with IFN, and assayed for luciferase and -galactosidase activities, as described under "Materials and Methods." Bars show the mean (n = 8) fold-increase in IFN-dependent luciferase activity relative to untreated cells, normalized for -galactosidase activity. Error bars represent the standard error of the mean. The asterisks indicate that both clonal lines expressing m1 IFNaR2 (U5A-m1.1 and U5A-m1.2) display a statistically significant increase in induced luciferase activity relative to the wt IFNaR2-expressing (U5A-wt) cells (p < 0.001 or p < 0.004, respectively). C, Stat2 protein levels are elevated in U5A cells complemented with m1 IFNaR2 constructs. Upper panel, cells were collected, counted, lysed, and the resulting lysates loaded directly onto a gel and immunoblotted with an anti-Stat2 antibody. Each lane contains lysate from the same number of U5A cells expressing the indicated construct. The position of Stat2 is indicated. Lower panel, similar to the upper panel except that ~1% of the amount of lysate used in the blot depicted in the upper panel was loaded in this case. Blotting was performed with an anti--actin antibody. The position of -actin protein is indicated.

Next, we performed a reporter gene assay, essentially identical to the one shown in Fig. 7. Fig. 8B confirms our results in the U2OS overexpression system. In general, the level of IFN-dependent reporter gene induction is lower, compared with U2OS cells, in the U5A cells complemented with wt IFNaR2 as well as the parental 2fTGH cells, which also express the wild-type gene. The difference in induced reporter gene activity between these two lines is not significant. However, both U5A clones expressing m1 IFNaR2 display a statistically significant enhancement of IFN-dependent reporter gene activity relative to U5A cells complemented with wt IFNaR2. The degree of enhancement is not proportional to the level of m1 IFNaR2 protein expression (compare Fig. 8, A and B).

We did not observe a consistent difference in the level of Stat2 tyrosine phosphorylation among the various U5A transfectants (data not shown), in contrast to our observations in the 293T overexpression system. However, both of the U5A clones complemented with m1 IFNaR2 express higher levels of Stat2 protein relative to the clone complemented with wt IFNaR2 (Fig. 8C). Densitometry of the data shown in Fig. 8C, as well as data from a replicate experiment performed on a separate set of cell extracts (data not shown), revealed an average increase of about 3.5-fold for Stat2 protein levels when normalized to -actin protein levels.

Mapping the IFNaR2-interacting Domain on Stat2-- To map the IFNaR2-interacting domain on Stat2, we generated truncated Stat2 derivatives and tested them in an in vitro assay similar to that employed in Figs. 1-3. Using STAT chimeras created by exchanging homologous sequences between Stat1 and Stat2, Li et al. (25) implicated a domain encompassing Stat2 residues 295-315 in the binding to IFNaR2. However, although we observed strong binding to full-length Stat2 (Figs. 1-3), we were unable to detect binding to constructs spanning residues 1-293, 1-323, and 123-517, respectively (Fig. 9A and data not shown). The construct spanning residues 136-702 was designed on the basis of proteolytic digestion and crystallographic data suggesting that both Stat1 and Stat3 form central core structures held together by hydrophobic interactions, which are topologically distinct from the extreme amino and carboxyl terminal domains (41, 42). A strong association was readily detected between this double-truncated Stat2 and wild-type GST-IFNaR2 (376-462), but not with an IFNaR2 mutant 1 fusion (Fig. 9B, compare lanes 3 and 4), indicating that amino and carboxyl termini are dispensable. In addition, because both recombinant proteins employed in Fig. 9B were purified from bacteria, the data indicate that Stat2 and IFNaR2 almost certainly bind directly to one another in eukaryotic cells without any intervening proteins.

View larger version (25K): [in this window] [in a new window]   Fig. 9.   Mapping the IFNaR2-interacting domain on Stat2. A, diagram of Stat2 constructs. The domains of Stat2 and the corresponding amino acid positions are indicated, along with the extent of each construct. Construction and expression is described under "Materials and Methods." Binding to IFNaR2 is indicated at the right (data for full-length Stat2 are in Figs. 1-3; data are not shown for non-interacting constructs). B, in vitro binding of IFNaR2 by Stat2-(136-702). Double-truncated His-tagged Stat2-(136-702) protein was expressed in E. coli, purified (see "Materials and Methods"), reacted with GST (lane 2), GST-IFNaR2-(376-462) (lane 3), or GST-m1 IFNaR2-(376-462) (lane 4) and immunoblotted with an anti-His tag antibody, as described in Fig. 1. Lane 1 contains the same amount of purified His-tagged Stat2-(136-702) as was used in the binding assays.

	DISCUSSION

TOP ABSTRACT INTRODUCTION MATERIALS AND METHODS RESULTS DISCUSSION REFERENCES

SH2 domain-mediated binding of Stat2 to tyrosine-phosphorylated IFNaR1 is well established as a critical protein-protein interaction required for signaling in response to IFN (10, 17, 25). In this study we have investigated a second interaction between Stat2 and the IFN receptor complex; the constitutive, SH2-independent interaction between Stat2 and IFNaR2. Our experimental approach consisted of two parts. First, we characterized binding between Stat2 and IFNaR2. In vitro binding between Stat2 and IFNaR2 was previously reported by Li et al. (25) and subsequently mapped to residues 404-462 of IFNaR2 (33). We confirmed these data (Fig. 1) and then narrowed the Stat2 binding domain to a 26-residue region, spanning amino acids 418-444 (Fig. 2). Within this domain, conserved acidic residues are crucial for Stat2 binding because their mutation severely diminishes the Stat2-IFNaR2 interaction both in vitro and in vivo (Figs. 3, 4, and 5A). A search for homologous sequences has revealed no similarity to known proteins, suggesting this Stat2 binding site may be unique to IFNaR2. The IFNaR2 interaction domain on Stat2 has not been as clearly defined. Neither Stat2 tyrosine phosphorylation nor an intact SH2 domain are required for the Stat2-IFNaR2 interaction (Fig. 1). Using Stat1-Stat2 chimeric proteins, Li et al. (25) have shown that a sequence spanning residues 295-315 of Stat2 is necessary for binding to IFNaR2. Although we observed an in vitro interaction using a Stat2 construct spanning residues 136-702 (Fig. 9), we were unable to detect binding to shorter fragments of Stat2 overlapping the region identified by Li and colleagues. Thus, residues 295-315 of Stat2, although necessary, may not be sufficient to mediate binding, and additional portions of Stat2 may be required. Alternately, because the central portion of Stat2 (residues 136-702) is apparently held together by a single, contiguous hydrophobic core (41, 42), proteins encoding fragments of this core may not be folded properly. To resolve this issue, we are currently mutating a core Stat2 construct to identify residues critical for this association.

Second, we investigated the physiologic effects of disrupting the Stat2-IFNaR2 interaction. The most important and consistent result of these studies is the finding that the m1 IFNaR2 construct, when overexpressed in 293T cells or when used to complement IFNaR2-deficient U5A cells, does not impair IFN-dependent induction of an ISRE-linked reporter gene (Figs. 7 and 8). These data indicate that the Stat2-IFNaR2 interaction is not required for signaling. The relatively small but reproducible enhancement of IFN-dependent reporter gene activity observed in these two independent experiments suggests that under physiologic conditions the Stat2 binding site on the IFNaR2 subunit might negatively regulate IFN signaling. Because we are uncertain of the molecular mechanism regulating this inhibitory effect, we consider this latter conclusion to be speculative at this time. When m1 IFNaR2 was overexpressed in 293T cells Stat2 tyrosine phosphorylation was enhanced (Fig. 6). However, the effect, although reproducible, was quite modest. Furthermore, in the U5A complementation experiments we did not observe a reproducible effect on Stat2 phosphorylation. Instead, we saw a definite increase in the level of total Stat2 protein (Fig. 8C). Thus, it is possible that the mechanism involved might modulate either Stat2 phosphorylation and/or stability. Clearly, a variety of other mechanisms that ultimately lead to an increase in ISRE-mediated gene transcription could be operative here, and this remains an area for future investigation.

Li et al. (25) correlated tyrosine phosphorylation and reporter gene activity with in vitro binding to IFNaR2 by various Stat1-2 chimeras. They concluded that the Stat2-IFNaR2 interaction is required for the IFN signaling and suggested that Stat2 predocks on IFNaR2 prior to its ligand-dependent recruitment to phosphorylated tyrosine 466 on IFNaR1. This model is at odds with our conclusions. Although differences in the experimental systems make direct comparisons difficult, we believe it is likely that the chimeric STAT constructs are exerting multiple effects on the pathway. In this regard, we find that overexpression of Stat2 fragments spanning residues 1-293 and 1-323, which do not bind IFNaR2, nonetheless inhibit ISRE-reporter gene activity.³ In contrast, in our studies mutation of residues 435-438 in IFNaR2 are likely to be more specific in effecting the interaction of IFNaR2 with Stat2. Therefore, the enhanced signaling we observe is probably a direct result of disrupting the Stat2-IFNaR2 interaction. More recently, Russel-Harde et al. (37) reported that the complementation of IFNaR2-deficient U5A cells with a carboxyl-terminal-truncated form of IFNaR2, which removes part of the Stat2 interaction domain, inhibits IFN-induced Stat2 activation and biologic activity. Again, although these results apparently contradict our findings, a number of reservations must be noted. Specifically, the Stat2 binding ability of the truncation construct was not assayed in these studies. Additionally, it remains possible that the truncation is effecting other regulatory interactions that occur in regions of the IFNaR2 protein distal to the Stat2 binding site that we have identified.

Nadeau et al. (33) expressed human IFN receptor subunits in mouse cells and concluded that the Stat2 interaction domain on IFNaR2 contributes to Stat2 recruitment to the receptor complex. This was based on the detection of low level Stat2 tyrosine phosphorylation in transfectants lacking the IFNaR1 tyrosine 466 docking site but containing the Stat2 binding region of IFNaR2. However, these authors also showed that multiple IFNaR2 sites stimulate low level Stat2 activation. Moreover, it is unclear if the receptor complex in this heterologous system accurately mimics the situation in human cells, as the involvement of endogenous murine receptors, or other proteins, cannot be ruled out. For example, studies on IFNaR1 tyrosine 466 performed using a similar heterologous human-murine approach (43) completely contradict the data obtained in human cells (10, 16, 25). Finally, IFN signaling has been observed in situations where IFNaR2 homodimerization is believed to occur, such as IFN treatment of Tyk2-deficient cells (7, 44, 45) and when employing chimeric IFNaR2 receptors (46). Because IFNaR1 is not in these receptor complexes, Stat2 cannot be recruited via tyrosine 466, and an alternative mechanism is presumably utilized. The IFNaR2-Stat2 interaction has been invoked as such an alternate, and we cannot exclude this possibility. However, it should be noted that none of these studies employed specific mutations within the IFNaR2 cytoplasmic domain to directly address the hypothesis that the Stat2 interaction with residues 340-462 of IFNaR2 is required for signaling. Additionally, the relevance of these experimental scenarios to the physiologic situation for IFN, where IFNaR1 and IFNaR2 contribute to the receptor complex, remains to be determined.

It has been proposed that an unidentified tyrosine phosphatase binds IFNaR2 near the region we have identified as a Stat2 binding site (47). Although it is conceivable that the Stat2-IFNaR2 interaction modulates the activity of such a phosphatase, we believe that this is unlikely for two reasons. First, deletions removing the residues 418-444 of IFNaR2 do not affect that activity of the phosphatase (47), even though this region is critical for Stat2 binding to IFNaR2 (Figs. 2 and 3). In addition, we do not see any change in the tyrosine phosphorylation of the receptor-associated JAK kinases (data not shown).

Finally, it should be noted that the in vivo binding results shown in Fig. 5 also explicitly fail to support the idea that IFNaR2 mediates an obligatory docking and/or predocking step in the process of Stat2 activation. First, triggering the signaling cascade by treating cells with IFN does not decrease the amount of Stat2 that is bound to the IFNaR2 subunit as might be expected if this site served a predocking function. In fact, we observed some increase in the amount of Stat2 binding to IFNaR2 following IFN treatment (Fig. 5). Second, very little tyrosine-phosphorylated Stat2 associates with IFNaR2 following IFN treatment, suggesting that this site is not acting as a functional docking site in and of itself. Furthermore, we have recently observed that recombinant Stat2 binds IFNaR2 more avidly than it binds IFNaR1 which is tyrosine-phosphorylated on residue 466.² These data are inconsistent with the idea that tyrosine-phosphorylated IFNaR1 recruits Stat2 from an interaction site on IFNaR2.

	ACKNOWLEDGEMENTS

We thank O. Colamonici (University of Illinois, Chicago) for the IFNaR2 cDNA clones, C. Schindler (Columbia University, College of Physicians and Surgeons) for anti-Stat2 antiserum, M. Brunda (Hoffman-La Roche) for IFN2, H. Young (Columbia University, College of Physicians and Surgeons) for 293T cells, and G. Stark (Lerner Research Institute, Cleveland Clinic Foundation) for U5A and 2fTGH cells.

	FOOTNOTES

^* This work was supported by Research Grant RG-2928A1-T from the National Multiple Sclerosis Society and by funds from the National Institutes of Health (CA56862).The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

^§ Supported by Institutional Training Grant CA09054 from the National Cancer Institute.

To whom correspondence should be addressed: University of California, Irvine, College of Medicine, Dept. of Pathology, Medical Sciences D450, Irvine, CA 92697-4800. Tel.: 949-824-4089; Fax: 949-824-2160; E-mail: jkrolews@uci.edu.

Published, JBC Papers in Press, January 10, 2002, DOI 10.1074/jbc.M111161200

² A. Z. Saleh and J. J. Krolewski, manuscript in preparation.

³ V.-P. Nguyen and J. J. Krolewski, unpublished data.

	ABBREVIATIONS

The abbreviations used are: IFN, interferon; JAK, Janus tyrosine kinase; STAT, signal transducers and activators of transcription; ISRE, interferon-stimulated responsive element; GST, glutathione S-transferase; wt, wild type; m1, mutant 1; SH2, Src homology 2 domain; HA, hemaggluttinin.

	REFERENCES

TOP ABSTRACT INTRODUCTION MATERIALS AND METHODS RESULTS DISCUSSION REFERENCES